Tag: Hepatotoxicity

While severe hepatic failure is a rare event, drug-induced liver injury is a known potential adverse effect of many disease-modifying therapies (DMTs) used for multiple sclerosis (MS). All patients should be informed about the potential for liver damage, as the incidence and underlying mechanisms can vary significantly between different MS drugs.

According to a 2017 study in the *Annals of the Rheumatic Diseases*, the risk of liver damage increases with higher alcohol consumption in patients taking methotrexate. This critical finding provides context to the common and serious question, 'Can you drink alcohol with methotrexate?', which primarily centers on the combined stress placed on the liver.

Liver test abnormalities have been reported in 10% to 50% of patients on long-term olanzapine therapy [1.2.2, 1.6.1]. The key question for many patients and clinicians is, **does olanzapine elevate liver enzymes** to a clinically significant degree, and what are the implications for treatment?

The human liver, responsible for processing over 90% of all drugs, plays a pivotal role in the clearance of many anesthetic agents. Understanding **what anesthetics are metabolized by the liver** is crucial for safe patient management, especially for individuals with compromised hepatic function. This guide explores how different anesthetic classes rely on the liver and the clinical implications involved.

According to regulatory updates, clinically significant liver injury has been identified as a risk associated with Ocrevus (ocrelizumab) and other anti-CD20 therapies. This confirms that Ocrevus can damage the liver, though the incidence is rare and monitoring is crucial.

According to the National Institutes of Health, liver injury from rifampin is a well-documented risk, ranging from mild enzyme elevations to severe and potentially fatal cases. The question 'Is rifampin hazardous?' is complex, requiring a careful look at both its powerful therapeutic benefits and its notable potential for serious adverse effects and drug interactions.

Yes, **Veozah is metabolized in the liver**, primarily through the cytochrome P450 (CYP) enzyme pathway. This crucial fact underlies specific monitoring recommendations and potential drug interactions for patients taking this non-hormonal treatment for menopausal hot flashes.

According to a 2024 FDA Drug Safety Communication, Veozah (fezolinetant) has been associated with rare but serious liver injury following post-marketing surveillance. This makes understanding the potential risks, including what are the rare side effects of veozah, crucial for patients considering this non-hormonal treatment for menopause symptoms.

Acute liver failure due to an acetaminophen overdose is a leading cause in the United States, yet it is often misunderstood which is harder on the liver, naproxen or Tylenol. The answer is complex and depends heavily on the specific circumstances, including dosage and individual health factors.

Losartan is a widely prescribed angiotensin II receptor blocker for hypertension, with a reported incidence of minor liver enzyme elevations of less than 2% during clinical trials. While generally considered safe, the potential for drug-induced hepatotoxicity is a rare but documented risk, leading many to ask: **Can losartan raise ALT levels?**